| Symbol | CHRS |
|---|---|
| Name | COHERUS ONCOLOGY, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 333 TWIN DOLPHIN DRIVE,SUITE 600, REDWOOD CITY, California, 94065, United States |
| Telephone | +1 650 649-3530 |
| Fax | — |
| — | |
| Website | https://www.coherus.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. Additional info from NASDAQ: |
2026-05-04 13:30
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
Read more
2026-04-29 22:03
New Form SCHEDULE 13G/A - Coherus Oncology, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001104659-26-051922 <b>Size:</b> 8 KB
Read more
2026-04-20 10:00
New Form ARS - Coherus Oncology, Inc. <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001104659-26-045272 <b>Size:</b> 1 MB
Read more
2026-04-20 09:27
New Form DEF 14A - Coherus Oncology, Inc. <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001104659-26-045251 <b>Size:</b> 2 MB
Read more
2026-04-14 18:21
New Form DEFA14A - Coherus Oncology, Inc. <b>Filed:</b> 2026-04-14 <b>AccNo:</b> 0001104659-26-043317 <b>Size:</b> 15 KB
Read more
2026-04-09 18:26
New Form PRE 14A - Coherus Oncology, Inc. <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001104659-26-041578 <b>Size:</b> 2 MB
Read more
2026-03-26 18:13
New Form SCHEDULE 13G/A - Coherus Oncology, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000907 <b>Size:</b> 7 KB
Read more
2026-03-09 20:40
(30% Negative) COHERUS ONCOLOGY, INC. (CHRS) Reports Q1 2026 Financial Results
Read more
2026-03-09 20:15
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
Read more
2026-03-02 14:30
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05479045 | A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metas… | Phase2 | Ovarian Cancer Stage IV | Not_Yet_Recruiting | 2026-09-01 | 2028-11-01 | ClinicalTrials.gov |
| NCT07277322 | Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver… | Phase1 | Metastatic Colorectal Cancer | Not_Yet_Recruiting | 2026-06-01 | 2030-12-31 | ClinicalTrials.gov |
| NCT07423078 | Window of Opportunity in Preserving Laryngeal Function Trial | Phase2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Recruiting | 2026-04-06 | 2031-04-30 | ClinicalTrials.gov |
| NCT07214987 | PDT For Induction Therapy For Head And Neck Cancer | Phase2 | Squamous Cell Carcinoma | Not_Yet_Recruiting | 2026-03-09 | 2029-09-01 | ClinicalTrials.gov |
| NCT07209189 | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition f… | Phase2 | Head and Neck Cancer | Recruiting | 2026-02-18 | 2030-12-01 | ClinicalTrials.gov |
| NCT07281716 | Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastat… | Phase1 | Metastatic Microsatellite Stable Colorectal Carcinoma | Recruiting | 2025-12-01 | 2028-12-15 | ClinicalTrials.gov |
| NCT07140679 | Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mism… | Phase2 | Localized Colon Carcinoma | Recruiting | 2025-09-19 | 2029-12-31 | ClinicalTrials.gov |
| NCT06940180 | Toripalimab With Chemotherapy for Sinus Cancer | Phase2 | Sinonasal Cancer | Recruiting | 2025-06-17 | 2029-02-01 | ClinicalTrials.gov |
| NCT06975293 | STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced C… | Phase1 | Solid Tumor | Recruiting | 2025-05-05 | 2028-06-29 | ClinicalTrials.gov |
| NCT06657144 | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Tr… | Phase1 | Metastatic Solid Tumor | Recruiting | 2025-04-01 | 2028-01-01 | ClinicalTrials.gov |
| NCT06389526 | A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors | Phase1 | Advanced or Metastatic Solid Tumors | Not_Yet_Recruiting | 2025-02-15 | 2028-05-30 | ClinicalTrials.gov |
| NCT06679985 | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Par… | Phase2 | Hepatocellular Carcinoma | Active_Not_Recruiting | 2024-12-20 | 2027-09-01 | ClinicalTrials.gov |
| NCT06457503 | A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Partici… | Phase4 | Nasopharyngeal Cancer Recurrent | Recruiting | 2024-11-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in P… | Phase1 | Advanced Solid Tumor | Terminated | 2023-04-26 | 2024-07-31 | ClinicalTrials.gov |
| NCT05635643 | Study of CHS-114 in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Recruiting | 2022-12-15 | 2027-01-01 | ClinicalTrials.gov |
| NCT05359861 | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With H… | Phase2 | Hepatocellular Carcinoma | Completed | 2022-04-12 | 2025-07-08 | ClinicalTrials.gov |
| NCT05177770 | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients … | Phase2 | Metastatic Castration-resistant Prostate Cancer | Terminated | 2022-01-17 | 2023-04-05 | ClinicalTrials.gov |
| NCT04662892 | An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca | — | Febrile Neutropenia | Unknown | 2020-08-01 | 2022-12-15 | ClinicalTrials.gov |
| NCT04374877 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tum… | Phase1 | Advanced Solid Tumor | Completed | 2020-04-22 | 2025-06-05 | ClinicalTrials.gov |
| NCT04336098 | Study of SRF617 in Patients With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Completed | 2020-03-16 | 2023-08-25 | ClinicalTrials.gov |
| NCT02650973 | Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1… | Phase1 | Healthy | Completed | 2016-02-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02489227 | Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis | Phase3 | Plaque Psoriasis | Completed | 2015-08-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT02486939 | A Long Term Safety Extension Study (CHS-0214-05) | Phase3 | Rheumatoid Arthritis | Completed | 2015-07-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02418104 | Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfi… | Phase1 | Immunity, Humoral | Completed | 2015-05-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02385851 | Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701… | Phase1 | Bioequivalence | Completed | 2015-02-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02134210 | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque P… | Phase3 | Plaque Psoriasis | Completed | 2014-06-16 | 2016-05-12 | ClinicalTrials.gov |
| NCT02115750 | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthr… | Phase3 | Rheumatoid Arthritis | Completed | 2014-05-01 | 2016-05-01 | ClinicalTrials.gov |
Total clinical trials: 27
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Toripalimab | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | NOT_YET_RECRUITING | NCT06389526 |
| CHS-1000 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | NOT_YET_RECRUITING | NCT06389526 |
| zimberelimab | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT05177770 |
| etrumadenant | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT05177770 |
| SRF617 | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | TERMINATED | NCT05177770 |
| Pegfilgrastim | Other | Phase PHASE1 | Bioequivalence | COMPLETED | NCT02385851 |
| CHS-1701 | Other | Phase PHASE1 | Bioequivalence | COMPLETED | NCT02385851 |
| Pegfilgrastim (Neulasta) | Other | Phase PHASE1 | Immunity, Humoral | COMPLETED | NCT02418104 |
| CHS-1701 | Other | Phase PHASE1 | Immunity, Humoral | COMPLETED | NCT02418104 |
| Pegfilgrastim | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02650973 |
| CHS-1701 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02650973 |
| CHS-0214 | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02486939 |
| CHS-0214 | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02115750 |
| Etanercept | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02115750 |
| CHS-0214 | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT02134210 |
| Etanercept | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT02134210 |
| Adalimumab | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT02489227 |
| CHS-1420 | Other | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT02489227 |
| Pegfilgrastim-Cbqv | Other | Preclinical | Febrile Neutropenia | UNKNOWN | NCT04662892 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04336098 |
| Albumin-Bound Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04336098 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04336098 |
| SRF617 | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04336098 |
| toripalimab (anti-PD-1) | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05757492 |
| CHS-006 (anti-TIGIT) | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05757492 |
| Cisplatin | Other | Phase PHASE2 | Sinonasal Cancer | RECRUITING | NCT06940180 |
| Radiation Therapy | Drug | Phase PHASE2 | Sinonasal Cancer | RECRUITING | NCT06940180 |
| Docetaxel | Other | Phase PHASE2 | Sinonasal Cancer | RECRUITING | NCT06940180 |
| Carboplatin | Other | Phase PHASE2 | Sinonasal Cancer | RECRUITING | NCT06940180 |
| Toripalimab | Other | Phase PHASE2 | Sinonasal Cancer | RECRUITING | NCT06940180 |
| Carboplatin | Other | Phase PHASE4 | Nasopharyngeal Cancer Recurrent | RECRUITING | NCT06457503 |
| Gemcitabine | Other | Phase PHASE4 | Nasopharyngeal Cancer Recurrent | RECRUITING | NCT06457503 |
| Cisplatin | Other | Phase PHASE4 | Nasopharyngeal Cancer Recurrent | RECRUITING | NCT06457503 |
| Toripalimab | Other | Phase PHASE4 | Nasopharyngeal Cancer Recurrent | RECRUITING | NCT06457503 |
| Bevacizumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT06679985 |
| Toripalimab | Other | Phase PHASE2 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT06679985 |
| Casdozokitug | Other | Phase PHASE2 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT06679985 |
| STC-15 monotherapy | Drug | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 in combination with toripalimab | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| Chemoradiotherapy or radiation | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab + Chemotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab | Other | Phase PHASE2 | Localized Colon Carcinoma | RECRUITING | NCT07140679 |
| Questionnaire Administration | Other | Phase PHASE2 | Localized Colon Carcinoma | RECRUITING | NCT07140679 |
| Computed Tomography | Other | Phase PHASE2 | Localized Colon Carcinoma | RECRUITING | NCT07140679 |
| Colonoscopy | Other | Phase PHASE2 | Localized Colon Carcinoma | RECRUITING | NCT07140679 |
| Biospecimen Collection | Other | Phase PHASE2 | Localized Colon Carcinoma | RECRUITING | NCT07140679 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Localized Colon Carcinoma | RECRUITING | NCT07140679 |
| Toripalimab | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04374877 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04374877 |
| CHS-388 | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04374877 |
| Docetaxel | Other | Phase PHASE2 | Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07214987 |
| Cisplatin | Other | Phase PHASE2 | Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07214987 |
| Toripalimab-tpzi | Other | Phase PHASE2 | Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07214987 |
| Toripalimab | Other | Phase PHASE1 | Metastatic Microsatellite Stable Colorectal Carcinoma | RECRUITING | NCT07281716 |
| Nadunolimab | Other | Phase PHASE1 | Metastatic Microsatellite Stable Colorectal Carcinoma | RECRUITING | NCT07281716 |
| Placebo | Other | Phase PHASE2 | Hepatocellular Carcinoma | COMPLETED | NCT05359861 |
| Bevacizumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | COMPLETED | NCT05359861 |
| Atezolizumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | COMPLETED | NCT05359861 |
| SRF388 | Other | Phase PHASE2 | Hepatocellular Carcinoma | COMPLETED | NCT05359861 |
| toripalimab | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05635643 |
| CHS-114 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05635643 |
| Cisplatin | Other | Phase PHASE1 | Metastatic Solid Tumor | RECRUITING | NCT06657144 |
| 5 Fluorouracil | Other | Phase PHASE1 | Metastatic Solid Tumor | RECRUITING | NCT06657144 |
| Toripalimab | Other | Phase PHASE1 | Metastatic Solid Tumor | RECRUITING | NCT06657144 |
| CHS-114 | Other | Phase PHASE1 | Metastatic Solid Tumor | RECRUITING | NCT06657144 |
| Radiation Therapy | Drug | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | RECRUITING | NCT07423078 |
| Paclitaxel | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | RECRUITING | NCT07423078 |
| Cisplatin | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | RECRUITING | NCT07423078 |
| Carboplatin | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | RECRUITING | NCT07423078 |
| Toripalimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | RECRUITING | NCT07423078 |
| Toripalimab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Dupilumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Toripalimab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Dupilumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Toripalimab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Dupilumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Toripalimab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Dupilumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Toripalimab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Dupilumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Toripalimab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Dupilumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Toripalimab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Dupilumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Toripalimab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Dupilumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Toripalimab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Dupilumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Toripalimab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Dupilumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Toripalimab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Dupilumab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Chemoradiotherapy or radiation | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab + Chemotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Chemoradiotherapy or radiation | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab + Chemotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Chemoradiotherapy or radiation | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab + Chemotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Chemoradiotherapy or radiation | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab + Chemotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Chemoradiotherapy or radiation | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab + Chemotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Chemoradiotherapy or radiation | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab + Chemotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Chemoradiotherapy or radiation | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab + Chemotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Chemoradiotherapy or radiation | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab + Chemotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Chemoradiotherapy or radiation | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab + Chemotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Chemoradiotherapy or radiation | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab + Chemotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Chemoradiotherapy or radiation | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab + Chemotherapy | Drug | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| STC-15 monotherapy | Drug | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 in combination with toripalimab | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 monotherapy | Drug | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 in combination with toripalimab | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 monotherapy | Drug | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 in combination with toripalimab | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 monotherapy | Drug | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 in combination with toripalimab | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 monotherapy | Drug | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 in combination with toripalimab | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 monotherapy | Drug | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 in combination with toripalimab | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 monotherapy | Drug | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 in combination with toripalimab | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 monotherapy | Drug | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 in combination with toripalimab | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 monotherapy | Drug | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| STC-15 in combination with toripalimab | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| Radiation Therapy | RADIATION | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | NOT_YET_RECRUITING | NCT07423078 |
| Paclitaxel | DRUG | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | NOT_YET_RECRUITING | NCT07423078 |
| Nadunolimab | DRUG | Phase PHASE1 | Metastatic Microsatellite Stable Colorectal Carcinoma | RECRUITING | NCT07281716 |
| Dupilumab | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | NOT_YET_RECRUITING | NCT07277322 |
| Docetaxel | DRUG | Phase PHASE2 | Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07214987 |
| Chemoradiotherapy or radiation | RADIATION | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Toripalimab + Chemotherapy | DRUG | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT07209189 |
| Questionnaire Administration | OTHER | Phase PHASE2 | Localized Colon Carcinoma | RECRUITING | NCT07140679 |
| Computed Tomography | PROCEDURE | Phase PHASE2 | Localized Colon Carcinoma | RECRUITING | NCT07140679 |
| Colonoscopy | PROCEDURE | Phase PHASE2 | Localized Colon Carcinoma | RECRUITING | NCT07140679 |
| Biospecimen Collection | PROCEDURE | Phase PHASE2 | Localized Colon Carcinoma | RECRUITING | NCT07140679 |
| Biopsy Procedure | PROCEDURE | Phase PHASE2 | Localized Colon Carcinoma | RECRUITING | NCT07140679 |
| STC-15 monotherapy | DRUG | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06975293 |
| Casdozokitug | DRUG | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT06679985 |
| 5 Fluorouracil | DRUG | Phase PHASE1 | Metastatic Solid Tumor | RECRUITING | NCT06657144 |
| Carboplatin | DRUG | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | NOT_YET_RECRUITING | NCT07423078 |
| Gemcitabine | DRUG | Phase PHASE4 | Nasopharyngeal Cancer Recurrent | RECRUITING | NCT06457503 |
| Cisplatin | DRUG | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | NOT_YET_RECRUITING | NCT07423078 |
| toripalimab | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05635643 |
| CHS-114 | DRUG | Phase PHASE1 | Metastatic Solid Tumor | RECRUITING | NCT06657144 |
| Toripalimab-tpzi | DRUG | Phase PHASE2 | Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07214987 |
| NY-ESO-1 Peptide vaccine | BIOLOGICAL | Phase PHASE2 | Ovarian Cancer Stage IV | NOT_YET_RECRUITING | NCT05479045 |
| Placebo | DRUG | Phase PHASE2 | Hepatocellular Carcinoma | COMPLETED | NCT05359861 |
| Bevacizumab | DRUG | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT06679985 |
| Atezolizumab | DRUG | Phase PHASE2 | Hepatocellular Carcinoma | COMPLETED | NCT05359861 |
| SRF388 | DRUG | Phase PHASE2 | Hepatocellular Carcinoma | COMPLETED | NCT05359861 |
| Pegfilgrastim-Cbqv | DRUG | Preclinical | Febrile Neutropenia | UNKNOWN | NCT04662892 |
| Toripalimab | DRUG | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | NOT_YET_RECRUITING | NCT07423078 |
| Pembrolizumab | DRUG | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04374877 |
| CHS-388 | DRUG | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04374877 |
| Adalimumab | DRUG | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT02489227 |
| CHS-1420 | DRUG | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT02489227 |
| Pegfilgrastim (Neulasta) | DRUG | Phase PHASE1 | Immunity, Humoral | COMPLETED | NCT02418104 |
| Pegfilgrastim | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02650973 |
| CHS-1701 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02650973 |
| CHS-0214 | DRUG | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02486939 |
| Etanercept | DRUG | Phase PHASE3 | Plaque Psoriasis | COMPLETED | NCT02134210 |
Total products: 181